Aethlon Medical Inc AEMD.OQ AEMD.O is expected to show no change in quarterly revenue when it reports results on November 13 for the period ending January 1 0001
LSEG's mean analyst estimate for Aethlon Medical Inc is for a loss of 19 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Aethlon Medical Inc is 3.86, above its last closing price of $0.43.
This summary was machine generated November 12 at 03:45 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments